New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:50 EDTAMAGAMAG Pharmaceuticals sees FY13 year-end cash/investment $206M-$211M
A 2013 year-end cash and investments balance of between $206 million and $211 million, not including the impact of business development transactions.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 26, 2015
10:00 EDTAMAGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:20 EDTAMAGAMAG Pharmaceuticals transferred with a Market Perform at FBR Capital
FBR Capital transferred coverage of AMAG Pharmaceuticals with a Market Perform rating, a downgrade from its previous rating of Outperform. FBR believes Feraheme growth will be limited to market share gains and that Makena expectations are fully realized at current valuation levels. The firm has a $42 price target for AMAG shares.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use